
From actress Jane Fonda giving an update on her cancer, to a patient with leukemia proving he was at the Sept. 11 attacks in New York City with an old newspaper clipping, here’s what’s happening in the cancer space this week.

From actress Jane Fonda giving an update on her cancer, to a patient with leukemia proving he was at the Sept. 11 attacks in New York City with an old newspaper clipping, here’s what’s happening in the cancer space this week.

It is important for cancer survivors to know their risk of developing heart disease, even years after treatment has ended, as they may be underdiagnosed or undertreated for them.

The FDA approved Imbruvica for children over the age of 1 who are experiencing chronic GVHD that has already been treated by one or more prior therapy.

Survivors of childhood cancer had higher rates of infection-related hospitalizations than their healthy peers, at both the five- and 10-year post-treatment mark.

From Dick Vitale receiving the Jimmy V Award at the 2022 ESPYs to a former triathlon champion opening up about his cancer experience, here’s what’s happening in the cancer space this week.

A first-in-human trial is investigating the safety and efficacy of the novel CAR-T cell therapy in patients relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma.

Findings from several studies have shown that childhood cancer survivors often stop attending much needed follow-up visits in the years following treatment.

Tafinlar plus Mekinist is now approved by the Food and Drug Administration to treat adults and children over the age of 6 who have BRAF V600-mutant advanced solid cancers.

From chef Gordon Ramsay sharing a meal with a 13-year-old fan with Ewing sarcoma, to a dermatologist on a playground spotting a mother’s skin cancer, here’s a look at what’s happening in the cancer space this week.

If approved, Omblastys will be the first FDA-approved drug for children with neuroblastoma that has spread to the central nervous system or leptomeninges.

Research showed that Hispanic children with neuroblastoma who are participating on clinical trials tended to have worse survival outcomes than others.

The FDA approved Vidaza for the treatment of pediatric patients with juvenile myelomonocytic leukemia.

From Philadelphia Flyers’ employees suing the organization after developing a rare blood cancer to experts proposing a new name for low-risk prostate cancer and an actor on Disney+’s “The Mandolorian” dying of cancer, here’s what is happening in the cancer space this week.

From liver cancer survivor planning to run the upcoming Boston Marathon with his organ donor to a common HIV drug showing promise in treating colorectal cancer, here’s what’s happening in the cancer space this week.

From Pfizer issuing a voluntary recall of three blood pressure drugs due to a high level of a cancer-causing chemical to “Today Show” co-ancho Hoda Kotb discussing her struggles with fertility after receiving a diagnosis of breast cancer, here’s what’s happening in the cancer space this week.

From a “Jeopardy!” winner taking her wig off on the gameshow to childhood patients with cancer in Ukraine being bussed to neighboring countries to safely receive treatment, here’s what’s happening in the cancer space this week.

Significant challenges include improving detection and response to inner ear side effects among cancer survivors following the use of certain drugs and therapies.

From the death of “America’s Got Talent” contestant Jane “Nightbirdie” Marczewski to “Good Morning America” anchor Robin Roberts announcing her partners breast cancer diagnosis, here’s what’s happening in the cancer space this week.

From long-term effects of pediatric cancer to a survivor fulfilling her dream of being an astronaut, CURE® looked back on its most-read childhood cancer stories of the year.

Patients with Down syndrome have an increased risk for leukemia during childhood, and toxicities related to treatment may be more common in this patient population.

Children with low skeletal muscle density were more likely to have hematologic toxicities from chemotherapy, but more research is needed to determine whether this measure is an accurate predictor of chemotoxicities in lymphoma.

The FDA approval of Rituxan plus chemotherapy is indicated for the treatment of children aged six months to 18 years who have various forms of lymphoma or a form of leukemia.

From Taylor Swift’s heartfelt tribute to a 4-year-old boy who died from cancer to Senator Amy Klobuchar’s announcement that she is cancer-free, here’s what’s happening in the cancer landscape this week.

Certain races/ethnicities and ages may have worse outcomes in Hodgkin lymphoma regardless of variation in upfront chemotherapy.

Children younger than five years old may have an increased risk for hearing loss from cisplatin-based therapies compared with older children, highlighting the potential need for more consistent monitoring for hearing loss in children with cancer.